What are the major opportunities in the Pulmonary Drugs market? What are the strategies for the Pulmonary Drugs market?

For detailed insights on the major opportunities and strategies in the Pulmonary Drugs market, Read More

How does the Pulmonary Drugs market relate to the overall economy and other similar markets?

For detailed insights on Pulmonary Drugs's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Pulmonary Drugs market growth? SWOT analysis of the Pulmonary Drugs market.

For detailed insights on the key dynamics influencing the Pulmonary Drugs market growth and SWOT analysis of the Pulmonary Drugs industry, Read More

Global Pulmonary Drugs Market Report 2025

Item added to cart!

Published : December 2025

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF

Purchase This Report

Pulmonary Drugs Global Market Report 2025

Name: Pulmonary Drugs Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes), By Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Pulmonary Drugs Market Overview

• Pulmonary Drugs market size has reached to $54.28 billion in 2024

• Expected to grow to $70.35 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%

• Growth Driver: Rising Prevalence Of Respiratory Diseases Driving Demand For Pulmonary Drugs Due To Increasing Infectious Disease Burden

• Market Trend: Innovative Single Inhaler Triple Therapy For Effective COPD Management

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pulmonary Drugs Market?

Pulmonary drugs refer to medications that target the respiratory system to improve lung function, reduce inflammation, and manage airway disorders. They are used for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other respiratory illnesses.

The main drug class of pulmonary drugs is inhaled corticosteroids, long-acting beta-2 agonists, antihistamines, vasodilators, short acting beta-2 agonists, and others. Inhaled corticosteroids are anti-inflammatory medications delivered directly to the lungs via inhalers to manage chronic respiratory conditions like asthma and COPD by reducing airway inflammation and preventing flare-ups. The various indications include asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, pulmonary arterial hypertension, cystic fibrosis, and others and they are distributed through several channels such as retail pharmacies, online pharmacies, and hospital pharmacies.

Pulmonary Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Pulmonary Drugs Market Size 2025 And Growth Rate?

The pulmonary drugs market size has grown strongly in recent years. It will grow from $54.28 billion in 2024 to $56.98 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to the rise in the prevalence of respiratory diseases, the increase in smoking rates, the growth in the geriatric population, the expansion of healthcare access, and the surge in pollution levels.

What Is The Pulmonary Drugs Market Growth Forecast?

The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to $70.35 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing healthcare infrastructure, rising prevalence of cardiovascular disease, expanding homecare treatments, rising awareness about pulmonary diseases, and rising prevalence of asthma. Major trends in the forecast period include technological advancements, AI-driven drug discovery, smart inhaler adoption, nanotechnology-based formulations, and gene therapy developments.

The forecast of 5.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. respiratory clinics by inflating prices of long-acting bronchodilators and mucolytic agents manufactured in Spain and India, resulting in reduced chronic obstructive pulmonary disease management options and higher pulmonary care expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Pulmonary Drugs Market Segmented?

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes

2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications

3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:

1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide

2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol

3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine

4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues

5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol

6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

What Is Driving The Pulmonary Drugs Market? Rising Prevalence Of Respiratory Diseases Driving Demand For Pulmonary Drugs Due To Increasing Infectious Disease Burden

The increasing prevalence of respiratory diseases is expected to propel the growth of the pulmonary drugs market going forward. Respiratory disorders refer to medical conditions that affect the lungs and airways, impairing normal breathing and oxygen exchange. Respiratory disorders are increasing due to the growing prevalence of smoking, leading to lung damage and chronic diseases. Pulmonary drugs play a crucial role in managing respiratory disorders by improving lung function, reducing inflammation, and relieving airway obstruction for better breathing. For instance, in November 2023, according to the Bureau of Labor Statistics, a US-based government agency, the illness rate among private industry employers in 2022 increased to 45.2 cases per 10,000 FTE workers, up from 37.7 cases in 2021. This rise was mainly attributed to a higher occurrence of respiratory illnesses, which grew from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Therefore, the rising respiratory diseases are driving the growth of the pulmonary drugs industry.

Who Are The Major Players In The Global Pulmonary Drugs Market?

Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

What Are The Key Trends Of The Global Pulmonary Drugs Market? Innovative Single Inhaler Triple Therapy For Effective COPD Management

Major companies operating in the pulmonary drugs market are focusing on developing innovative therapies, such as single-inhaler triple therapy (SITT), to enhance treatment efficacy, improve patient adherence, and simplify medication regimens for better disease management. Single-inhaler triple therapy (SITT) is a treatment that combines three different medications in a single inhaler to manage chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) more effectively. For instance, in April 2022, GlaxoSmithKline Pharmaceuticals Limited, an India-based pharmaceutical company, launched Trelegy Ellipta, India's first single-inhaler triple therapy (SITT) for patients suffering from chronic obstructive pulmonary disease (COPD). This therapy combines fluticasone furoate, umeclidinium, and vilanterol to improve lung function and reduce symptom exacerbations. The innovative Ellipta inhaler ensures accurate dosing and enhances patient adherence compared to multiple-inhaler therapies. With over 100 million COPD patients in India, this launch aims to simplify treatment and improve patient outcomes.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Pulmonary Drugs Market? Roivant Sciences Expands Respiratory Portfolio With Acquisition Of Pulmonary Hypertension Drug From Bayer

In September 2024, Roivant Sciences Ltd., a US-based biotechnology company, acquired medicine for pulmonary hypertension manufactured by Bayer AG for an undisclosed amount. With this acquisition, Roivant aims to expand its respiratory portfolio and advance innovative treatments for pulmonary hypertension, enhancing patient outcomes and addressing unmet medical needs. Bayer AG is a Germany-based company that manufactures pulmonary drugs, including treatments for respiratory conditions such as pulmonary hypertension.

What Is The Regional Outlook For The Global Pulmonary Drugs Market?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pulmonary Drugs Market?

The pulmonary drugs market consists of the sales of inhalers, nebulizers, bronchodilators, anti-inflammatory agents, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Pulmonary Drugs Industry?

The pulmonary drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Pulmonary Drugs Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$56.98 billion
Revenue Forecast In 2034	$70.35 billion
Growth Rate	CAGR of 5.4% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The pulmonary drugs market covered in this report is segmented – 1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes 2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications 3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies Subsegments: 1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide 2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol 3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine 4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues 5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol 6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Request for Sample
Customization Scope	Explore Purchase Options
Pricing And Purchase Options

1. Executive Summary

2. Pulmonary Drugs Market Characteristics

3. Pulmonary Drugs Market Trends And Strategies

4. Pulmonary Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Pulmonary Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Pulmonary Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Pulmonary Drugs Market Growth Rate Analysis

5.4. Global Pulmonary Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Pulmonary Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Pulmonary Drugs Total Addressable Market (TAM)

6. Pulmonary Drugs Market Segmentation

6.1. Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Inhaled Corticosteroids

Long Acting Beta-2 Agonists

Antihistamines

Vasodilators

Short Acting Beta-2 Agonists

Other Drug Classes

6.2. Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Allergic Rhinitis

Pulmonary Arterial Hypertension

Cystic Fibrosis

Other Indications

6.3. Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Retail Pharmacies

Online Pharmacies

Hospitals Pharmacies

6.4. Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Beclomethasone

Budesonide

Fluticasone

Mometasone

Ciclesonide

6.5. Global Pulmonary Drugs Market, Sub-Segmentation Of Long Acting Beta-2 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Salmeterol

Formoterol

Indacaterol

Olodaterol

Vilanterol

6.6. Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Cetirizine

Loratadine

Fexofenadine

Diphenhydramine

Levocetirizine

6.7. Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Endothelin Receptor Antagonists

Phosphodiesterase-5 Inhibitors

Prostacyclin Analogues

6.8. Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists (SABA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Albuterol

Levalbuterol

Terbutaline

Fenoterol

Pirbuterol

6.9. Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monoclonal Antibodies

Enzymes

Antibiotics

Antileukotrienes

7. Pulmonary Drugs Market Regional And Country Analysis

7.1. Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pulmonary Drugs Market

8.1. Asia-Pacific Pulmonary Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pulmonary Drugs Market

9.1. China Pulmonary Drugs Market Overview

9.2. China Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pulmonary Drugs Market

10.1. India Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pulmonary Drugs Market

11.1. Japan Pulmonary Drugs Market Overview

11.2. Japan Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pulmonary Drugs Market

12.1. Australia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pulmonary Drugs Market

13.1. Indonesia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pulmonary Drugs Market

14.1. South Korea Pulmonary Drugs Market Overview

14.2. South Korea Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pulmonary Drugs Market

15.1. Western Europe Pulmonary Drugs Market Overview

15.2. Western Europe Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pulmonary Drugs Market

16.1. UK Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pulmonary Drugs Market

17.1. Germany Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pulmonary Drugs Market

18.1. France Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pulmonary Drugs Market

19.1. Italy Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pulmonary Drugs Market

20.1. Spain Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pulmonary Drugs Market

21.1. Eastern Europe Pulmonary Drugs Market Overview

21.2. Eastern Europe Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pulmonary Drugs Market

22.1. Russia Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pulmonary Drugs Market

23.1. North America Pulmonary Drugs Market Overview

23.2. North America Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pulmonary Drugs Market

24.1. USA Pulmonary Drugs Market Overview

24.2. USA Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pulmonary Drugs Market

25.1. Canada Pulmonary Drugs Market Overview

25.2. Canada Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pulmonary Drugs Market

26.1. South America Pulmonary Drugs Market Overview

26.2. South America Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pulmonary Drugs Market

27.1. Brazil Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pulmonary Drugs Market

28.1. Middle East Pulmonary Drugs Market Overview

28.2. Middle East Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pulmonary Drugs Market

29.1. Africa Pulmonary Drugs Market Overview

29.2. Africa Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pulmonary Drugs Market Competitive Landscape And Company Profiles

30.1. Pulmonary Drugs Market Competitive Landscape

30.2. Pulmonary Drugs Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck Sharp & Dohme Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Pulmonary Drugs Market Other Major And Innovative Companies

31.1. Sanofi S.A.

31.2. AstraZeneca plc

31.3. Novartis AG

31.4. GlaxoSmithKline plc

31.5. Mylan N.V.

31.6. Teva Pharmaceutical Industries Ltd.

31.7. Boehringer Ingelheim International GmbH

31.8. Grifols S.A.

31.9. Chiesi Farmaceutici S.p.A.

31.10. Cipla Limited

31.11. Lupin Pharmaceuticals Inc.

31.12. United Therapeutics Corporation

31.13. Mallinckrodt Pharmaceuticals plc

31.14. Glenmark Pharmaceuticals Limited

31.15. Circassia Pharmaceuticals plc

32. Global Pulmonary Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Drugs Market

34. Recent Developments In The Pulmonary Drugs Market

35. Pulmonary Drugs Market High Potential Countries, Segments and Strategies

35.1 Pulmonary Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Pulmonary Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Pulmonary Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Pulmonary Drugs Market, Sub-Segmentation Of Long Acting Beta-2 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists (SABA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Pfizer Inc. Financial Performance

Table 81: F. Hoffmann-La Roche Ltd. Financial Performance

Table 82: Merck Sharp & Dohme Limited Financial Performance

Table 83: AbbVie Inc. Financial Performance

Table 84: Bayer AG Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Pulmonary Drugs Market, Sub-Segmentation Of Inhaled Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Pulmonary Drugs Market, Sub-Segmentation Of Long Acting Beta-2 Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Pulmonary Drugs Market, Sub-Segmentation Of Antihistamines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Pulmonary Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Pulmonary Drugs Market, Sub-Segmentation Of Short-Acting Beta-2 Agonists (SABA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Pulmonary Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Pulmonary Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Pulmonary Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Pulmonary Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Pulmonary Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Pulmonary Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Pfizer Inc. Financial Performance

Figure 81: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 82: Merck Sharp & Dohme Limited Financial Performance

Figure 83: AbbVie Inc. Financial Performance

Figure 84: Bayer AG Financial Performance

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

Global Vutrisiran Market Trends: Regional Breakdowns and Strategic Insights

Vyndaqel Outlook 2034: Key Drivers, Trends, and Market Frontiers

Functional Dyspepsia DrugMarket Overview 2025–2034: CAGR Trends, Long-Term Growth Paths, and Business Implications

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Pulmonary Drug Delivery Devices Global Market Report 2025 – By Product Type (Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers), By Application (Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Other ...

Lung Cancer Drugs Global Market Report 2025 – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC))...

Inhalable Drugs Global Market Report 2025 – By Product (Aerosol, Dry Powder Formulation, Spray), By Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Other Distribution Channels), By Application (Respiratory Dise...

Asthma Drugs Global Market Report 2025 – By Type Of Asthma (Allergic, Non-Allergic), By Asthma Trigger Type (Adult-Onset Asthma, Child-Onset Asthma, Cough-Induced Asthma, Exercise-Induced Asthma, Occupational Asthma, Noc...

Pulmonary Arterial Hypertension Global Market Report 2025 – By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Route of Administration (Or...

Inhaled Antibiotics Global Market Report 2025 – By Product Type( Aerosol or Metered Dose Inhaler, Dry Powder Formulation, Spray, Other Types), By Application( Pneumonia, Asthma, Bronchitis, Other Applications), By End-Us...

Anti-Asthmatic And COPD Drugs Market 2021 - By Drug Class (Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs), By End User (Asthma Patients, COPD Patients), By Distribution Channel (Gener...

Frequently Asked Questions

What is the definition of the Pulmonary Drugs market?

How will the Pulmonary Drugs market drivers and restraints affect the market dynamics? What forces will shape the Pulmonary Drugs industry going forward?

The market major growth driver - Rising Prevalence Of Respiratory Diseases Driving Demand For Pulmonary Drugs Due To Increasing Infectious Disease Burden. For further insights on this market, request a sample here

What is the forecast market size or the forecast market value of the Pulmonary Drugs market?

The pulmonary drugs market size has grown steadily in recent years. It will grow from $54.28 billion in 2024 to $56.98 billion in 2025 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to the rise in the prevalence of respiratory diseases, the increase in smoking rates, the growth in the geriatric population, the expansion of healthcare access, and the surge in pollution levels. The pulmonary drugs market size is expected to see strong growth in the next few years. It will grow to " $70.35 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing healthcare infrastructure, rising prevalence of cardiovascular disease, expanding homecare treatments, rising awareness about pulmonary diseases, and rising prevalence of asthma. Major trends in the forecast period include technological advancements, AI-driven drug discovery, smart inhaler adoption, nanotechnology-based formulations, and gene therapy developments. For further insights on this market, request a sample here

How is the Pulmonary Drugs market segmented?

The pulmonary drugs market covered in this report is segmented –
1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes
2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies Subsegments:
1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide
2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol
3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine
4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues
5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol
6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes For further insights on this market, request a sample here

Which region has the largest share of the Pulmonary Drugs market? What are the other regions covered in the report?

North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Who are the major players in the Pulmonary Drugs market?

What are the key trends in the Pulmonary Drugs market?

Major trends in this market include Innovative Single Inhaler Triple Therapy For Effective COPD Management. For further insights on this market, request a sample here.